Quest Diagnostics Hits New 52-Week High at $187.96, Surpassing Previous Low

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 187.96 on September 23, 2025. This achievement underscores the company's robust performance in the market, particularly as it has recorded a remarkable 32.16% increase over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.38% during the same period.
As a mid-cap company with a market capitalization of USD 29,720 million, Quest Diagnostics operates within the miscellaneous industry. The stock's price-to-earnings (P/E) ratio stands at 28.00, reflecting its valuation in relation to earnings. Additionally, the company boasts a notable dividend yield of 87.16%, indicating a strong return for shareholders.

Financial metrics such as a debt-to-equity ratio of 0.76 and a return on equity of 14.78% further illustrate Quest Diagnostics' solid financial health. The stock's previous 52-week low was recorded at USD 146.17, highlighting the significant upward movement in its price. This new high marks an important moment for the company as it continues to navigate the competitive landscape.